Systems pharmacology: a combination strategy for improving efficacy of PD-1/PD-L1 blockade. Issue 5 (20th April 2021)

• Record Type: Journal Article
• Authors: Zheng, Chunli; Xiao, Yue; Chen, Chuang; Zhu, Jinglin; Yang, Ruijie; Yan, Jiangna; Huang, Ruifei; Xiao, Wei; Wang, Yonghua; Huang, Chao
• Is Part Of: Briefings in bioinformatics. Volume 22:Issue 5(2021)
• Publication Date: 2021-04-20
• Subjects: systems pharmacology -- combination strategy of PD-1/PD-L1 blockade -- natural products -- tumor microenvironment -- oxymatrine; Genetics -- Data processing -- Periodicals; Molecular biology -- Data processing -- Periodicals; Genomes -- Data processing -- Periodicals; 572.80285
• DOI: 10.1093/bib/bbab130
• Languages: English
• ISSNs: 1467-5463

Abstract

Abstract: Targeting tumor microenvironment (TME), such as immune checkpoint blockade (ICB), has achieved increased overall response rates in many advanced cancers, such as non-small cell lung cancer (NSCLC), however, only in a fraction of patients. To improve the overall and durable response rates, combining other therapeutics, such as natural products, with ICB therapy is under investigation. Unfortunately, due to the lack of systematic methods to characterize the relationship between TME and ICB, development of rational immune-combination therapy is a critical challenge. Here, we proposed a systems pharmacology strategy to identify resistance regulators of PD-1/PD-L1 blockade and develop its combinatorial drug by integrating multidimensional omics and pharmacological methods. First, a high-resolution TME cell atlas was inferred from bulk sequencing data by referring to a high-resolution single-cell data and was used to predict potential resistance regulators of PD-1/PD-L1 blockade through TME stratification analysis. Second, to explore the drug targeting the resistance regulator, we carried out the large-scale target fishing and the network analysis between multi-target drug and the resistance regulator. Finally, we predicted and verified that oxymatrine significantly enhances the infiltration of CD8 + T cells into TME and is a powerful combination agent to enhance the therapeutic effect of anti-PD-L1 in a mouse model of lung adenocarcinoma. Overall, the systems pharmacology strategy offers a paradigm to identify combinatorial drugs for ICB therapy with a systems biology perspective of drug-target-pathway-TME phenotype-ICB combination.